Waltham, Mass.-based Alere Inc. is discontinuing its Inratio and Inratio 2 PT/INR blood monitoring devices after the FDA said a study of the products' software enhancements was inadequate. The company's stock fell more than 3 percent on the news, which will result in charges of between $70 million and $90 million this year.